European cancer mortality predictions for the year 2016 with focus on leukaemias

M. Malvezzi\textsuperscript{1,2}, G. Carioli\textsuperscript{2}, P. Bertuccio\textsuperscript{2}, T. Rosso\textsuperscript{2}, P. Boffetta\textsuperscript{3}, F. Levi\textsuperscript{4}, C. La Vecchia\textsuperscript{2*} & E. Negri\textsuperscript{1}

\textsuperscript{1}Department of Epidemiology, IRCCS-Istituto di Ricerche Farmacologiche ‘Mario Negri’, Milan; \textsuperscript{2}Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy; \textsuperscript{3}Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; \textsuperscript{4}Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland

Received 21 December 2015; revised 8 January 2016; accepted 11 January 2016

Background: Current cancer mortality statistics are important for public health decision-making and resource allocation. Age-standardized rates and numbers of deaths are predicted for 2016 in the European Union (EU).

Patients and methods: Population and death certification data for stomach, colorectum, pancreas, lung, breast, uterus, prostate, leukaemias and total cancers were obtained from the World Health Organization database and Eurostat. Figures were derived for the EU, France, Germany, Italy, Poland, Spain and the UK. Projected numbers of deaths by age group were obtained for 2016 by linear regression on estimated numbers of deaths over the most recent time period identified by a joinpoint regression model.

Results: Projected total cancer mortality trends for 2016 in the EU are favourable in both sexes with rates of 133.5/100 000 men and 85.2/100 000 women (8% and 3% falls since 2011) corresponding to 753 600 and 605 900 deaths in men and women for a total number of 1 359 500 projected cancer deaths (+3% compared with 2011, due to population ageing). In men, lung, colorectal and prostate cancer have fallen 11%, 5% and 8%, respectively, since 2011. Breast and colorectal cancer trends in women are favourable (8% and 7% falls, respectively), but lung and pancreatic cancer rates have risen 5% and 4% since 2011 reaching rates of 14.4 and 5.6/100 000 women. Leukaemias show favourable projected mortality for both sexes and all age groups, with stronger falls in the younger age groups. All ages rates are 4.0/100 000 men and 2.5/100 000 women, with falls of 14% and 12% respectively.

Conclusion: The 2016 predictions for EU cancer mortality confirm the favourable trends in rates particularly for men. Lung cancer is likely to be the leading site for female cancer rates. Continuing falls in mortality, larger in children and young adults, are predicted in leukaemias, essentially due to advancements in management and therapy, and their subsequent adoption across Europe.

Key words: cancer, Europe, mortality, projections, leukaemia, time trends

Introduction

We previously published short-term cancer mortality predictions for the European Union (EU) as a whole, and for its six more populous countries up to the year 2015 [1–5]. On the basis of the World Health Organization (WHO) mortality database [6], here we provide the corresponding figures for the year 2016. In the present paper, we also focus specifically on leukaemias, giving predicted numbers of deaths and death rate estimates for this important group of neoplasms in various age groups, and discuss their declines across sexes, countries and age groups.

Materials and methods

This work is an update to the previous articles on predicted European cancer mortality; hence, similar methods are used [1, 5].

We obtained official death certification data from the WHO database (WHOISIS) [6] for the stomach, colorectum, pancreas, lung, breast, uterus (cervix and corpus), prostate, leukaemias and total cancer (malignant and benign) mortality.

Figures were derived for the EU (28 countries as of July 2013) in the period 1970–2011 and up to the most recent available year for 6 major European countries: France (2011), Germany (2013), Italy (2012), Poland (2013), Spain (2013) and the UK (2013). Details on data sources and preparation are given in a supplementary Appendix, available at Annals of Oncology online.

From the matrices of certified deaths and resident populations, we computed age-specific number of deaths and rates for each 5-year age group (from 0–4 to 85+ years) and calendar year. Age-standardized rates (world standard population) per 100 000 men and women, at all ages, were computed using the direct

*Correspondence to: Prof. Carlo La Vecchia, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Via Augusto Vanzetti 5, Milan 20122, Italy. Tel: +39-02-50-320-854; Fax: +39-02-50-320-866; E-mail: carlo.lavecchia@unimi.it

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
method, on the basis of the world standard population [7]. For leukaemias, rates for the 0–14, 15–44 and 45–69 years age groups were also computed.

We fit a logarithmic Poisson count data joinpoint regression model to the numbers of certified deaths for each 5-year age group to identify the most recent trend segment (see supplementary Appendix, available at Annals of Oncology online) [8].

We applied a linear regression to mortality data for each 5-year age group over the most recent trend segment identified by the joinpoint model to compute the predicted age-specific certified numbers of deaths and the corresponding 95% prediction intervals (PIs) [9]. Predicted age-specific numbers of deaths and the predicted population data from Eurostat were used to compute the predicted age-standardized death rates with 95% PIs [10].

results

Table 1 shows the total numbers of predicted cancer deaths (rounded to the nearest hundred) and the death rate predictions with corresponding 95% PIs for selected neoplasms for 2016, in the EU as a whole, as well as the 2011 recorded data. Overall, 1 359 500 EU citizen are projected to die of cancer in 2016 (753 600 men and 605 900 women), compared with the 1 314 787 cancer deaths recorded in 2011 (734 259 men and 580 528 women). These figures correspond to age-standardized rates of 133.5/100 000 men and 85.2/100 000 women predicted for 2016, compared with 144.6 men and 88.1 women recorded in 2011. Thus, a 7.7% fall in rates for men and a 3.3% one in women are predicted between 2011 and 2016, despite an increase of +3.3% in the absolute number of cancer deaths.

Thus, a 7.7% fall in rates for men and a 3.3% one in women are compared with 144.6 men and 88.1 women recorded in 2011. 133.5/100 000 men and 85.2/100 000 women predicted for 2016, corresponding to a 4.6% fall, followed by prostate cancer, with a predicted rate of 10.6/100 000 men with a 7.8% fall since 2011. In women, prostate cancer shows the third highest predicted rate (10.6/100 000, with a 7.8% fall since 2011). In women, mortality from lung cancer is still rising and it is likely to be the neoplasm with the highest mortality rate in the EU in women in 2016, with a predicted rate of 14.4/100 000, corresponding to 89 700 predicted deaths (14.8% of total female cancer deaths), and to a 5.4% rise in rates since 2011.

Breast cancer has the second highest projected rate (14.3/100 000, with a 7.6% fall since 2011), but the total number of deaths remains highest for this neoplasm (92 300). Between the ages of 55 and 79 years, more deaths from female lung than breast cancer were predicted whereas, in elderly women, an excess in breast cancer deaths persisted.

The cancer with the second largest impact in men is that of the colorectum, with a predicted rate of 16.2/100 000 corresponding to a 4.6% fall, followed by prostate cancer, with a predicted rate of 10.6/100 000 men with a 7.8% fall since 2011. In women, colorectal cancer shows the third highest predicted rate (9.3/100 000, with a 7.0% fall since 2011); deaths from this cancer represent 12.8% of total cancer deaths in the EU in 2016, with 173 400 projected deaths.

Pancreatic cancer shows rising predicted death rates in women (5.6/100 000, +3.9%), whereas the predicted rate of

<table>
<thead>
<tr>
<th>European Union</th>
<th>Observed number of deaths 2011</th>
<th>Predicted number of deaths 2016</th>
<th>Lower prediction limit (95%)</th>
<th>Upper prediction limit (95%)</th>
<th>Observed ASR* 2011</th>
<th>Predicted ASR* 2016</th>
<th>Lower prediction limit (95%)</th>
<th>Upper prediction limit (95%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex Cancer Stomach</td>
<td>36 332</td>
<td>33 800</td>
<td>33 105</td>
<td>34 585</td>
<td>7.06</td>
<td>5.98</td>
<td>5.84</td>
<td>6.11</td>
</tr>
<tr>
<td>Men Colorectum</td>
<td>90 412</td>
<td>95 600</td>
<td>94 432</td>
<td>96 707</td>
<td>16.96</td>
<td>16.18</td>
<td>15.96</td>
<td>16.40</td>
</tr>
<tr>
<td>Pancreas</td>
<td>39 056</td>
<td>42 600</td>
<td>41 974</td>
<td>43 250</td>
<td>7.93</td>
<td>7.88</td>
<td>7.76</td>
<td>8.01</td>
</tr>
<tr>
<td>Lung</td>
<td>185 707</td>
<td>183 800</td>
<td>181 553</td>
<td>186 115</td>
<td>38.07</td>
<td>34.01</td>
<td>33.57</td>
<td>34.45</td>
</tr>
<tr>
<td>Prostate</td>
<td>72 330</td>
<td>75 800</td>
<td>74 672</td>
<td>76 999</td>
<td>11.47</td>
<td>10.58</td>
<td>10.39</td>
<td>10.77</td>
</tr>
<tr>
<td>Leukaemias</td>
<td>22 694</td>
<td>23 000</td>
<td>22 453</td>
<td>23 465</td>
<td>4.57</td>
<td>4.39</td>
<td>4.30</td>
<td>4.09</td>
</tr>
<tr>
<td>All neoplasms (malignant and benign)</td>
<td>734 259</td>
<td>753 600</td>
<td>748 212</td>
<td>759 068</td>
<td>144.63</td>
<td>133.52</td>
<td>132.46</td>
<td>134.58</td>
</tr>
<tr>
<td>Women Stomach</td>
<td>23 883</td>
<td>21 400</td>
<td>20 740</td>
<td>22 015</td>
<td>3.31</td>
<td>2.76</td>
<td>2.67</td>
<td>2.86</td>
</tr>
<tr>
<td>Colorectum</td>
<td>77 478</td>
<td>77 800</td>
<td>76 641</td>
<td>78 953</td>
<td>10.03</td>
<td>9.33</td>
<td>9.18</td>
<td>9.49</td>
</tr>
<tr>
<td>Pancreas</td>
<td>38 693</td>
<td>43 000</td>
<td>42 376</td>
<td>43 587</td>
<td>5.39</td>
<td>5.60</td>
<td>5.50</td>
<td>5.69</td>
</tr>
<tr>
<td>Lung</td>
<td>79 474</td>
<td>89 700</td>
<td>88 177</td>
<td>91 144</td>
<td>13.61</td>
<td>14.35</td>
<td>14.05</td>
<td>14.64</td>
</tr>
<tr>
<td>Breast</td>
<td>91 291</td>
<td>92 300</td>
<td>91 060</td>
<td>93 544</td>
<td>15.44</td>
<td>14.27</td>
<td>14.03</td>
<td>14.52</td>
</tr>
<tr>
<td>Uterus (cervix and corpus)</td>
<td>28 614</td>
<td>28 900</td>
<td>28 287</td>
<td>29 485</td>
<td>5.00</td>
<td>4.69</td>
<td>4.58</td>
<td>4.80</td>
</tr>
<tr>
<td>Leukaemias</td>
<td>18 751</td>
<td>19 100</td>
<td>18 661</td>
<td>19 529</td>
<td>2.78</td>
<td>2.46</td>
<td>2.37</td>
<td>2.55</td>
</tr>
<tr>
<td>All neoplasms (malignant and benign)</td>
<td>580 528</td>
<td>605 900</td>
<td>601 438</td>
<td>610 265</td>
<td>88.12</td>
<td>85.21</td>
<td>84.54</td>
<td>85.87</td>
</tr>
</tbody>
</table>

7.9/100 000 in men only shows a 0.5% fall compared with 2011. The corresponding total deaths are 85 600, that is 6.3% of all predicted cancer deaths. Cancer of the uterus, stomach and leukaemias each represent <5% of total cancer deaths and show persistent declines.

Figure 2 illustrates trends in all age-standardized cancer mortality rates for men and women in quinquennia centered from 1972 to 2007, and the predicted rates for 2016 with PIs for all cancers. Trends in total cancer mortality in the EU are favourable in both sexes; in men, rates have been falling since the late 1980s, whereas in women they have been favourable over the entire period, though in recent years the falls in women were less pronounced than in men.

Figure 3 gives corresponding trends for major cancer sites. Stomach cancer mortality shows the greatest falls over the whole period. In men, lung cancer also has shown appreciable falls in mortality since the late 1980s as breast cancer has shown in women. The only exceptions to these generally favourable trends in the EU are pancreatic cancer in both sexes and lung cancer in women: pancreatic cancer mortality rates have been showing steady rises in women, whereas in men it seems to have stabilized. Over the last decades, female lung cancer has shown strong rises. See supplementary Appendix, available at *Annals of Oncology* online, for individual country data and analyses (supplementary Tables S1–S9 and Figure S1, available at *Annals of Oncology* online).

Table 2 gives age-standardized leukaemia mortality rates in the 2000–2004 and 2005–2009 quinquennia, the predicted mortality rate for 2016 and the percent difference between the 2016 prediction and 2007 (2005–2009 quinquennium), for all ages, 0–14, 15–44 and 45–69 years age groups, for male and female, in the six studied countries and the EU as a whole. In 2000–2004, leukaemia mortality rates for all ages in men were between 5 and 6/100 000, and showed favourable trends in all countries and the EU as a whole, giving predicted rates for 2016 between 4 (Spain and the UK) and 5/100 000 (Poland and Italy). Similarly, in women, in 2000–2004, leukaemia mortality rates for all ages in men were between 5 and 6/100 000, and showed favourable trends in all countries and the EU as a whole, giving predicted rates for 2016 between 4 (Spain and the UK) and 5/100 000 (Poland and Italy). The overall decline between 2007 and 2016 approached 16% in women and 19% in men. The falls, however, were greatest in children (38% in males, 20% in females) and young adults (26% in males, 22% in females). The predicted rates for 2016 in the EU are
The fall in tobacco-related cancer mortality is the main driver for the fall in overall cancer mortality in men, whereas in women the fall is mainly due to cancers amenable to treatment and subject to early diagnosis, i.e. cancers of the breast and uterus (as well as stomach and colorectum), whereas lung cancer trends remain upwards [4, 5].

Lung cancer mortality reflects the differences between smoking prevalence trends between the sexes and European countries [12]. The 2016 projection confirms the steady declines of lung cancer mortality in men and the increases in women, with lung cancer rates much higher than breast cancer rates in young and middle age women, indicating that the excess lung cancer mortality is likely to be greater in the near future. In the UK, where female projections for this cancer have been unstable, updated data to 2013 brought about a downward projected trend; this would be in line with lung cancer age-period-cohort analyses for this country [13].

Improved therapeutic procedures and advancements in diagnosis and screening have determined favourable trends in several cancer sites and are among the main drivers of the decline in cancer mortality in women, including breast and cervical cancer. However, a slowdown in the falls in uterine cancer mortality is apparent for several countries. The exception to these descending rates is the UK, particularly in elderly women and hence likely due to endometrial cancer linked to overweight and diabetes [14]. National mortality data do not allow separate analysis of cervix and corpus uteri cancers.

Prostate cancer trends are also descending, albeit with variable degrees across countries. The role of screening practices is still debated, but it may have had a role in the measured and projected falls in mortality [15, 16]. Effective modern therapies, including radiotherapy and anti-androgens, and management protocols are, however, the major determinants of the favourable trends, not only in the middle aged but also in the elderly [15]. The excess in mortality for elderly Polish men is likely due to delayed adoption of these therapies.

EU colorectal cancer mortality reductions are brought mainly by northern and western European countries thanks to better awareness of the disease, screening, early diagnosis and patient management protocols and treatments [17, 18]. However, projected rises in Spain and particularly in Poland (which has the highest rates in Europe) emphasize the need to rationalize these strategies in southern and eastern Europe.

The favourable trends in mortality from stomach cancer are projected to continue into 2016. Thus, gastric cancer remains one of the main drivers of the total favourable trends in both sexes; the most probable determinants of these trends are a more affluent and varied diet, better food conservation and the fall in Helicobacter pylori infection across generations [19, 20]. However, falls seem to be slowing down, particularly in women and in countries where rates are already low [20, 21]. This suggests that mortality levels of this tumour are reaching an asymptote. National mortality data do not allow to discriminate cardias versus corpus and pyloric cancer. It is therefore possible that such a levelling in rates is due to lack of declines in cardias and cardio-oesophageal-junction cancer mortality.

Pancreatic cancer is the tumour with the least favourable outlook in both sexes; the most probable determinants of these trends are a more affluent and varied diet, better food conservation and the fall in Helicobacter pylori infection across generations [19, 20]. However, falls seem to be slowing down, particularly in women and in countries where rates are already low [20, 21]. This suggests that mortality levels of this tumour are reaching an asymptote. National mortality data do not allow to discriminate cardias versus corpus and pyloric cancer. It is therefore possible that such a levelling in rates is due to lack of declines in cardias and cardio-oesophageal-junction cancer mortality.

Pancreatic cancer is the tumour with the least favourable outlook in both sexes. However, in men, projections for the EU give a stable mortality rate rather than a rising one, while in women the unfavourable trend is confirmed [3–5]. Aetiology for this cancer is still largely uncertain, but smoking plays a relevant role.
role accounting for 20%–30% of cases in various populations [22–24]. Consequently, the observed differences in trends between sexes may well be explained by the different smoking trends. The other relevant recognized risk factors are obesity and diabetes, whose prevalence has increased over recent years in most populations [25].

**Figure 3.** Age-standardized (world population) EU male and female cancer mortality rate trends in quinquennia from 1970–1974 to 2005–2009 and predicted rates for 2016 with 95% prediction intervals (PIs). Men: stomach (squares), colorectum (circles), pancreas (triangles), lung (crosses), prostate (xs) and leukaemias (diamonds). Women: stomach (squares), colorectum (circles), pancreas (triangles), lung (crosses), breast (xs), uterus (diamonds) and leukaemias (inverted triangles).

**Table 2.** Age-standardized leukemia mortality rates for all ages in selected European countries and the EU as a whole, in men and women, for all ages, 0–14, 15–44 and 45–69 years in the quinquennia 2000–2004, 2005–2009 and the predicted rates for 2016, with percentage differences between 2016 and 2007 (2005–2009 quinquennium)

<table>
<thead>
<tr>
<th></th>
<th>Men</th>
<th></th>
<th>Women</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ASR&lt;sup&gt;a&lt;/sup&gt; 2000–04</td>
<td>ASR&lt;sup&gt;a&lt;/sup&gt; 2005–09</td>
<td>Predicted ASR&lt;sup&gt;a&lt;/sup&gt; 2016</td>
<td>% Difference 2016 versus 2007</td>
</tr>
<tr>
<td><strong>Selected European countries</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>5.46</td>
<td>5.06</td>
<td>4.00</td>
<td>−0.21</td>
</tr>
<tr>
<td>Germany</td>
<td>5.02</td>
<td>4.56</td>
<td>4.13</td>
<td>−0.09</td>
</tr>
<tr>
<td>Italy</td>
<td>5.69</td>
<td>5.24</td>
<td>4.49</td>
<td>−0.14</td>
</tr>
<tr>
<td>Poland</td>
<td>5.63</td>
<td>5.53</td>
<td>4.53</td>
<td>−0.18</td>
</tr>
<tr>
<td>Spain</td>
<td>4.79</td>
<td>4.31</td>
<td>3.56</td>
<td>−0.17</td>
</tr>
<tr>
<td>UK</td>
<td>4.66</td>
<td>4.40</td>
<td>3.74</td>
<td>−0.15</td>
</tr>
<tr>
<td><strong>EU</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All ages</td>
<td>5.23</td>
<td>4.85</td>
<td>3.95</td>
<td>−0.19</td>
</tr>
<tr>
<td>0–14 years&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.10</td>
<td>0.87</td>
<td>0.54</td>
<td>−0.38</td>
</tr>
<tr>
<td>15–44 years&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.50</td>
<td>1.28</td>
<td>0.95</td>
<td>−0.26</td>
</tr>
<tr>
<td>45–69 years</td>
<td>9.19</td>
<td>8.39</td>
<td>6.79</td>
<td>−0.19</td>
</tr>
</tbody>
</table>

<sup>a</sup>ASR, age-standardized mortality rates using the World Standard Population.

<sup>b</sup>Predictions estimated with a log-linear model.
Inferences on leukaemia mortality are complicated by the nature of this heterogeneous group of diseases; national mortality data do not allow for their individual separation and analysis. Projections for these cancers in 2016 are favourable in both sexes for most age groups and countries, but the falls are appreciably larger at younger ages. Therapeutic advancements are the main drivers of these trends; these include better diagnosis, multidrug chemotherapy and immunotherapy protocols assisted by toxicity limiting therapies and improved radiotherapy [26, 27]. The distribution of leukaemias by type varies by age. Children are generally affected by acute lymphoblastic leukaemia (ALL) that is also frequent in adolescents and young adults. In contrast, chronic leukaemia, in particular chronic lymphocytic leukaemia (CLL), is common in the elderly. ALL is mostly curable and 5-year survival in children has reached over 90% in optimum conditions [28]. Improvements have also been observed in adolescents and adults; these are attained through improved disease management and, in recent years, relapse control using allogenic haematopoietic stem-cell transplants and immunotherapy, as well as using paediatric inspired regimens in young adults [29–33]. Stem-cell transplants and new chemotherapy regimens have also brought improvements in acute myelogenous leukaemia (AML) that is relatively common in adult and elderly patients [34, 35]. Chronic leukaemia is hardly curable, but long-term survival has been achieved in chronic myeloid leukaemia, since the introduction of tyrosine kinase inhibitors [36–39]. Some improvement in survival in Europe, though not as strong as in the United States [40], has also been observed in CLL even though it is mainly in patients under 75 years of age. These improvements are due to better diagnosis, management and therapy including anti-CD20 antibodies like obinutuzumab combined with chlorambucil [41, 42].

Given large size of the underlying population, EU cancer mortality predictions should not be affected by random oscillations or major unexpected factors. However, if some factors were to determine changes within the last few years, the model would not be able to account for them. Also the linear models used tend to underestimate future rates, particularly under certain conditions (e.g. asymptotic behaviours after strong descending trends); hence, in some scenarios, predictions may be overly optimistic within a global picture of declining trends [43].

Updated data from the WHO made it possible to compute EU age-standardized mortality rates for 2011, and compare these data with our predictions [1]. All estimates, with the exceptions, in women, for stomach and uterine cancers and leukaemias, are within a 5% difference. Stomach and uterine cancer trends fall within the model’s predictive limits, while for leukaemias, discrepancy between predicted and observed rates affects the younger age groups that are weighted heavily in the world standard population.

In conclusion, EU cancer mortality predictions for 2016 confirm the favourable trends in rates (although in the absence of a decline in the absolute number of deaths) particularly for men. This is essentially due to larger declines in tobacco smoking in men than in women in recent decades. Despite the
steady favourable trends in breast and uterine (mainly cervix) cancer mortality, they also confirm that lung cancer is likely to be the leading site for cancer rates in EU women. With specific reference to leukaemias, they confirm the favourable trends in mortality due to the advancement in therapy, particularly for acute leukaemia in children and young adults.

**funding**

This work was conducted with the contribution of the Italian Association for Cancer Research (AIRC, project N. 14360), within the COST Action (BM1214) EU-Pancreas, and MIUR (Ministero dell’ Istruzione, dell’ Università e della Ricerca), with an SIR (Scientific Independence of Young Researchers) 2014 grant (project RBSI1465UH).

**disclosure**

The authors have declared no conflicts of interest.

**references**